Compare USEG & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | PRPO |
|---|---|---|
| Founded | 1966 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 44.4M |
| IPO Year | 1995 | 2000 |
| Metric | USEG | PRPO |
|---|---|---|
| Price | $0.89 | $28.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 15.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.21 | ★ 92.15 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,379,000.00 | $24,049,000.00 |
| Revenue This Year | $114,854.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.66 | $7.05 |
| 52 Week High | $2.75 | $33.63 |
| Indicator | USEG | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 48.86 |
| Support Level | $0.66 | $25.95 |
| Resistance Level | $1.08 | $29.66 |
| Average True Range (ATR) | 0.10 | 2.34 |
| MACD | -0.01 | -0.29 |
| Stochastic Oscillator | 4.89 | 31.95 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.